The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

The best companies will pay you to own them, sharing their profits via dividends. These high-quality stocks continuously grow ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed ...

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...